Regent Attman called the meeting of the Committee on Economic Development and Technology Commercialization of the University System of Maryland Board of Regents to order in public session at 12:05 p.m.

At 12:06 p.m., Regent Attman read the Convening in Closed Session statement, citing State Government Article Section 3-305(b)(14) of the Open Meetings Act to discuss issues specifically exempted in the Act from the requirement for public consideration. Regent Attman moved and Regent Gossett seconded to convene in closed session. In response to the motion, the Committee members voted unanimously to convene in closed session for the reasons stated on the Convening in Closed Session statement.

The regents in attendance were Mr. Attman, Mr. Brady, Ms. Comitz, Mr. Gossett, Dr. Gourdine, Senator Kelly, Mr. Pevenstein, and Mr. Rauch. Also participating in the meeting were Dr. Caret, Mr. Vivona, Mr. Balakrishnan, Mr. Darmody, Ms. Doyle, Mr. Hughes, Dr. Jarrell, Ms. Arthur, and Assistant Attorney General Elena Langrill.

1. The committee was briefed on the USM’s considerations regarding the National Cancer Institute’s rebid of the contract to operate its Federally Funded Research and Development Center (FFRDC) located in Frederick, Maryland. The FFRDC serves as a unique biomedical resource for the development of new technologies and the translation of basic science discoveries into novel agents for the prevention, diagnosis, and treatment of cancer, AIDS, and other diseases.

The closed session was adjourned at 12:37 p.m.

Respectfully submitted,

Gary L. Attman, Chair
Committee on Economic Development and Technology Commercialization